Poster
A Phase 2/3 Study of BLU-263, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis (ISM) and Monoclonal Mast Cell Activation Syndrome (mMCAS)
Author
Mariana Castells
Condition
Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome
Drug target
KIT D816V
Drug moa
Tyrosine Kinase Inhibitor
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-AAAAI-2022-HARBOR-BLU-263-Indolent-Systemic-Mastocytosis.pdf
3 organizations
1 product
Product
BLU-263Organization
Blueprint MedicinesOrganization
University of Michigan